Sotera Health Co

Sotera Health Co (SHC) Stock Analysis

$17.730

-0.468 (-2.64%)At close

Loading chart…
High
18.020
Open
17.820
VWAP
17.79
Volume
2.28M
Mkt Cap
3.37B
Low
17.625
Amount
40.56M
EV/EBITDA, TTM
11.35

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

AI analysis of Sotera Health Co (SHC)

Buy

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

Valuation Metrics

The current forward P/E ratio for Sotera Health Co (SHC) is 17.76, compared to its 5-year average forward P/E of 18.02.

Forward P/E

Fair
5Y Average P/E
18.02
Current P/E
17.76
Overvalued
21.74
Undervalued
14.30

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
11.46
Current EV/EBITDA
11.35
Overvalued
13.67
Undervalued
9.25

Forward P/S

Fair
5Y Average P/S
3.96
Current P/S
3.93
Overvalued
5.10
Undervalued
2.83

Alphio AI Price Scenarios for SHC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SHC

$12.30

Scenario price

B

Base

Base · 50%SHC

$11.71

Scenario price

B

Bear

Bear · 25%SHC

$10.60

Scenario price

Whales holding SHC

L

Lakewood Capital Management, LP

+ HoldingSHC

+3.60%

3M Return

S

Sculptor Capital Management, Inc.

+ HoldingSHC

-5.19%

3M Return

A

Ancora Advisors LLC

+ HoldingSHC

-5.49%

3M Return

G

Greenlight Capital, Inc.

+ HoldingSHC

-8.03%

3M Return

V

Voss Capital, LP

+ HoldingSHC

-8.34%

3M Return

T

Two Seas Capital LP

+ HoldingSHC

-9.02%

3M Return

Events Timeline

2026-08-06 (ET)

07:30:00

Sotera Health Q2 Revenue Reaches $321.38M, Exceeds Expectations

07:30:00

Consensus Raises FY26 Revenue Outlook to $1.24B

2026-05-12 (ET)

09:30:00

Goldman Sachs Sole Bookrunner, Deal Range $15.27-$15.43

2026-05-11 (ET)

17:30:00

Goldman Sachs Acts as Sole Book Running Manager for Offering

16:40:00

Sotera Health Company Launches Secondary Offering of 31.84M Shares

News

SHC FAQ — answered by Alphio AI

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading